Molecular Partners Valuation
| MOLN Stock | USD 4.61 0.04 0.86% |
At this time, the firm appears to be undervalued. Molecular Partners secures a last-minute Real Value of $6.27 per share. The latest price of the firm is $4.61. Our model forecasts the value of Molecular Partners from analyzing the firm fundamentals such as Shares Owned By Institutions of 9.60 %, return on equity of -0.51, and Current Valuation of 31.89 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Molecular Partners' valuation include:
Price Book 1.3905 | Enterprise Value | Enterprise Value Ebitda 1.2347 | Price Sales 199.5555 | Forward PE 1.7775 |
Undervalued
Today
Please note that Molecular Partners' price fluctuation is slightly risky at this time. Calculation of the real value of Molecular Partners is based on 3 months time horizon. Increasing Molecular Partners' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Molecular Partners is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Molecular Stock. However, Molecular Partners' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.61 | Real 6.27 | Target 12.08 | Hype 4.67 |
The intrinsic value of Molecular Partners' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Molecular Partners' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Molecular Partners AG helps investors to forecast how Molecular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Molecular Partners more accurately as focusing exclusively on Molecular Partners' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Molecular Partners' intrinsic value based on its ongoing forecasts of Molecular Partners' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Molecular Partners' closest peers.
Molecular Partners Cash |
|
Molecular Partners Total Value Analysis
Molecular Partners AG is now expected to have valuation of 31.89 M with market capitalization of 172.22 M, debt of 2.44 M, and cash on hands of 267.13 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Molecular Partners fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
31.89 M | 172.22 M | 2.44 M | 267.13 M |
Molecular Partners Investor Information
The company has price-to-book ratio of 1.39. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners recorded a loss per share of 2.1. The entity had not issued any dividends in recent years. Based on the key indicators related to Molecular Partners' liquidity, profitability, solvency, and operating efficiency, Molecular Partners AG is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Molecular Partners Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Molecular Partners has an asset utilization ratio of 3.14 percent. This suggests that the Company is making $0.0314 for each dollar of assets. An increasing asset utilization means that Molecular Partners AG is more efficient with each dollar of assets it utilizes for everyday operations.Molecular Partners Profitability Analysis
Based on Molecular Partners' profitability indicators, Molecular Partners AG may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Molecular Partners' ability to earn profits and add value for shareholders.Net Loss | First Reported 2012-12-31 | Previous Quarter -20.4 M | Current Value -11.8 M | Quarterly Volatility 23.5 M |
For Molecular Partners profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Molecular Partners to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Molecular Partners utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Molecular Partners's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Molecular Partners over time as well as its relative position and ranking within its peers.
Molecular Partners Earnings per Share Projection vs Actual
The next projected EPS of Molecular Partners is estimated to be -0.2608 with future projections ranging from a low of -0.33 to a high of -0.1474. Molecular Partners' most recent 12-month trailing earnings per share (EPS TTM) is at -2.1. Please be aware that the consensus of earnings estimates for Molecular Partners AG is based on EPS before non-recurring items and includes expenses related to employee stock options.Molecular Partners Earnings Estimation Breakdown
The calculation of Molecular Partners' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Molecular Partners is estimated to be -0.2608 with the future projection ranging from a low of -0.33 to a high of -0.1474. Please be aware that this consensus of annual earnings estimates for Molecular Partners AG is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.33 Lowest | Expected EPS | -0.15 Highest |
Molecular Partners Earnings Projection Consensus
Suppose the current estimates of Molecular Partners' value are higher than the current market price of the Molecular Partners stock. In this case, investors may conclude that Molecular Partners is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Molecular Partners' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 5 | 53.74% | 0.0 | -0.2608 | -2.1 |
Molecular Partners Ownership Allocation
Molecular Partners maintains a total of 37.4 Million outstanding shares. Roughly 90.4 % of Molecular Partners outstanding shares are held by general public with 9.6 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Molecular Partners Profitability Analysis
The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (40.4 M).About Molecular Partners Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Molecular Partners AG. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Molecular Partners based exclusively on its fundamental and basic technical indicators. By analyzing Molecular Partners's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Molecular Partners's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Molecular Partners. We calculate exposure to Molecular Partners's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Molecular Partners's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -38.3 M | -36.4 M | |
| Pretax Profit Margin | (12.50) | (11.88) | |
| Operating Profit Margin | (14.16) | (13.46) | |
| Net Loss | (12.50) | (11.88) | |
| Gross Profit Margin | (9.84) | (9.35) |
Molecular Partners Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 34 M | |
| Forward Price Earnings | 1.7775 |
Molecular Partners Current Valuation Indicators
Molecular Partners' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Molecular Partners' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Molecular Partners, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Molecular Partners' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Molecular Partners' worth.When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Will Biotechnology sector continue expanding? Could Molecular diversify its offerings? Factors like these will boost the valuation of Molecular Partners. Expected growth trajectory for Molecular significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Molecular Partners data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Molecular Partners' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.